Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-PD trial of dapansutrile in early Parkinson's disease
ISRCTN16806940Phase 2Recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of dapansutrile in Parkinson's disease (PD) (3 arms), sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Adverse events during double-blind treatment. Started Feb 2025; status: recruiting.
02
Drugs
dapansutrile
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN16806940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16806940.